PRN: Global Psoriatic Arthritis Market 2015-2019 - Segmentation by Mechanism of Action and Analysis of TNF inhibitors, PDE4 Inhibitors, & Interleukin Blockers

14/gen/2016 17:10:53 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Psoriatic Arthritis Market 2015-2019 - Segmentation by Mechanism of Action and Analysis of TNF inhibitors, PDE4 Inhibitors, & Interleukin Blockers


DUBLIN, Jan. 14, 2016 /PRNewswire/ --

Research and Markets ( has announced the addition of the "Global Psoriatic Arthritis Market 2015-2019" report to their offering.

The global market for psoriatic arthritis is expected to witness moderate growth during the forecast period and factors like the increase in penetration of biologic therapies are expected to augment the prospects for growth in this market.

Additionally, the recent launch of products like Otezla and Stelara is also expected to boost market growth during the forecast period, resulting in its moderate CAGR of nearly 5% by 2019.

Some emerging trends are expected to boost the global psoriatic arthritis market. The dominance of the market by biologics in the treatment of psoriatic arthritis patients is one such trend. It is expected that biologics will be the preferred treatment option of the medical profession as well as the patients themselves. This will increase the number of treatment-seeking patients and result in an increase in the overall consumption of drugs for this condition.

According to the report, the global psoriatic arthritis market is driven by several factors. The presence of growing unmet needs for appropriate drugs is one of the major factors propelling the growth of the market.

Further, the report states that many branded drugs present for the treatment of psoriatic arthritis are soon going to lose their patent protection. Expiry of patents results in the loss of exclusivity of that specific drug, leading to a rapid decline in its sales. Therefore, this is expected to have a negative impact on the revenue of the branded drugs used to treat psoriatic arthritis.

Leading vendors in this market are

  • Abbvie
  • Amgen
  • Janssen Pharmaceuticals
  • Celgene
  • UCB

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Product profiles

Part 04: Market research methodology

Part 05: Introduction

Part 06: Disease overview

Part 07: Pipeline portfolio

Part 08: Novel mechanisms targeted by pipeline candidates

Part 09: Market landscape

Part 10: Market segmentation by MoA

Part 11: Market segmentation by type of molecule

Part 12: Market segmentation by severity of disease

Part 13: Market segmentation by route of administration

Part 14: Market segmentation by dosage form

Part 15: Geographical segmentation

Part 16: Market drivers

Part 17: Impact of drivers

Part 18: Market challenges

Part 19: Impact of drivers and challenges

Part 20: Market trends

Part 21: Vendor landscape

Part 22: Key vendor analysis

For more information visit

Media Contact:

Laura Wood, +353-1-481-1716,


blog comments powered by Disqus è un servizio offerto da Factotum Srl